– March 1, 2012
March 1, 2012
View Issues
-
Axitinib for Advanced Renal Cell Carcinoma
This randomized, controlled, open-label, multicenter Phase 3 trial compared axitinib with sorafenib as second-line therapy for metastatic renal clear-cell cancer. The results showed that axitinib extended progression-free survival by 2 months more than sorafenib (6.7 months vs 4.7 months), and had a superior objective response rate (19.4% vs 9.4%). -
Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer
In a prospective trial conducted from 2004-2010, 21 patients (median age 65 years) with a clinical complete response after chemoradiotherapy were followed closely per a stringent wait-and-see policy consisting of MRI, endosopies, and CT scans. These patients were compared to 20 patients prospectively who underwent surgery and were found to have a pathologic complete response. -
Management of an Asymptomatic Renal Mass in a 78-Year-Old Man with Comorbidities
An asymptomatic 78-year-old retired accountant presented to his physician with intractable hiccups. Physical examination, complete blood count, and imaging studies did not reveal a cause of the hiccups, and after several days the symptom disappeared. However, upon review of the abdominal CT scan obtained in evaluation of the hiccups, a right renal mass was defined. -
Aspirin Reduces Colorectal Cancer Occurrence in Patients with Lynch Syndrome: Implications for Cancer Prevention
Long-term follow-up of Lynch syndrome patients who completed 2 years of treatment (aspirin or placebo) on the CAPP2 colorectal cancer prevention trial revealed a significant reduction in colorectal cancer development. This was the first large-scale colon cancer prevention trial using aspirin as an intervention. Implications for the prevention of sporadic colon cancer remain conjectural, however tempting it is to extrapolate these findings to the general adult population. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.